After the company provided a significant update with regards to one of its products, AzurRx BioPharma Inc (NASDAQ: AZRX) stock rallied strongly on Thursday and has emerged as a stock that could be tracked closely by investors.
After the update from the company with regards to its exocrine pancreatic insufficiency treatment product MS 1819, the AzurRx stock rallied by as much as 35% and displayed strong momentum. The company announced that as part of the Phase 2b OPTION 2 extension study, the first two patients have been administered the medicine.
It is a major development for the company and the optimism about the stock among investors is understandable. Not too long ago, AzurRx had also announced that it was going to have an additional study arm in this particular phase of the clinical trial. The two patients who have been administered doses of MS 1819 are going to be treated for two weeks.